L

Lunit Inc
KOSDAQ:328130

Watchlist Manager
Lunit Inc
KOSDAQ:328130
Watchlist
Price: 41 450 KRW 0.61% Market Closed
Market Cap: ₩1.5T

P/FCFE

-70
Current
72%
More Expensive
vs 3-y average of -40.7

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
-70
=
Market Cap
₩1.1T
/
Free Cash Flow to Equity
₩-18.5B

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
-70
=
Market Cap
₩1.1T
/
Free Cash Flow to Equity
₩-18.5B

Valuation Scenarios

Lunit Inc is trading above its industry average

If P/FCFE returns to its Industry Average (22.5), the stock would be worth ₩-13 334.61 (132% downside from current price).

Statistics
Positive Scenarios
0/2
Maximum Downside
-132%
Maximum Upside
No Upside Scenarios
Average Downside
127%
Scenario P/FCFE Value Implied Price Upside/Downside
Current Multiple -70 ₩41 450
0%
Industry Average 22.5 ₩-13 334.61
-132%
Country Average 15.1 ₩-8 916.92
-122%

Forward P/FCFE
Today’s price vs future free cash flow to equity

Not enough data available to calculate forward P/FCFE

Peer Comparison

All Multiples
P/FCFE
P/E
All Countries
Close
Market Cap P/FCFE P/E
KR
Lunit Inc
KOSDAQ:328130
1.5T KRW -70 -17.8
JP
Medical Data Vision Co Ltd
TSE:3902
37.9T JPY 88.6 227.5
US
Cerner Corp
LSE:0R00
31.3B USD 36.2 53.1
US
Veeva Systems Inc
NYSE:VEEV
28.1B USD 20.3 30.9
AU
Pro Medicus Ltd
ASX:PME
14.2B AUD 119.4 60.6
JP
M3 Inc
TSE:2413
1T JPY 23.5 20.5
SE
Sectra AB
STO:SECT B
49.2B SEK 79.2 91.5
US
Doximity Inc
NYSE:DOCS
4.6B USD 15.1 19.3
US
Waystar Holding Corp
NASDAQ:WAY
4B USD 8.6 35
IN
Inventurus Knowledge Solutions Ltd
NSE:IKS
283.9B INR -201.6 42.8
CN
Winning Health Technology Group Co Ltd
SZSE:300253
19.1B CNY 80 -62.1
P/E Multiple
Earnings Growth PEG
KR
L
Lunit Inc
KOSDAQ:328130
Average P/E: 64.6
Negative Multiple: -17.8
N/A N/A
JP
Medical Data Vision Co Ltd
TSE:3902
227.5
62%
3.7
US
C
Cerner Corp
LSE:0R00
53.1
N/A N/A
US
Veeva Systems Inc
NYSE:VEEV
30.9
27%
1.1
AU
Pro Medicus Ltd
ASX:PME
60.6
29%
2.1
JP
M3 Inc
TSE:2413
20.5
16%
1.3
SE
Sectra AB
STO:SECT B
91.5
14%
6.5
US
Doximity Inc
NYSE:DOCS
19.3
15%
1.3
US
W
Waystar Holding Corp
NASDAQ:WAY
35
55%
0.6
IN
I
Inventurus Knowledge Solutions Ltd
NSE:IKS
42.8
N/A N/A
CN
Winning Health Technology Group Co Ltd
SZSE:300253
Negative Multiple: -62.1
69%
N/A

Market Distribution

Lower than 100% of companies in Korea
Percentile
0th
Based on 719 companies
0th percentile
-70
Low
0.2 — 8.1
Typical Range
8.1 — 28.4
High
28.4 —
Distribution Statistics
Korea
Min 0.2
30th Percentile 8.1
Median 15.1
70th Percentile 28.4
Max 21 200

Lunit Inc
Glance View

Market Cap
1.5T KRW
Industry
Health Care

Lunit Inc., founded in South Korea, stands as a pioneering force in the application of artificial intelligence within the realm of medical technology. As a company at the intersection of healthcare and cutting-edge AI, Lunit crafts advanced solutions that enhance the diagnostic processes in radiology and oncology. The company's name, derived from "learning unit," underscores its mission to employ deep learning as a core component in transforming medical diagnostics. At the heart of Lunit’s operations are their flagship products, Lunit INSIGHT and Lunit SCOPE, which are designed to empower physicians by providing highly accurate diagnostic readings and treatment predictions. With this technology, Lunit aims to reduce diagnostic errors and improve the efficiency of medical imaging analysis, ultimately enhancing patient treatment outcomes. Lunit generates revenue through strategic partnerships and sales of their AI software solutions to hospitals and healthcare providers globally. The company's business model involves not only licensing its AI technologies but also integrating them with existing medical imaging equipment, thus enhancing the value derived from traditional diagnostic tools. By collaborating with prominent medical device manufacturers and healthcare institutions, Lunit ensures both the scalability and adaptability of its products in diverse clinical settings. Additionally, they actively engage in research collaborations and pilot programs to further their technological advancements and expand their market presence. Through these endeavors, Lunit is steadily carving out a crucial role in the healthcare sector by offering AI-driven solutions that promise to revolutionize patient care.

Intrinsic Value
4 925.02 KRW
Overvaluation 88%
Intrinsic Value
Price ₩41 450
L
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett